Get the Stockscreener App
2.22
9.02%
-0.22
After Hours:
2.17
-0.05
-2.25%
Scisparc Ltd stock is traded at $2.22, with a volume of 51.04M.
It is down -9.02% in the last 24 hours and down -44.78% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$2.44
Open:
$3.01
24h Volume:
51.04M
Relative Volume:
9.81
Market Cap:
$1.19M
Revenue:
$1.31M
Net Income/Loss:
$-7.47M
P/E Ratio:
-0.3078
EPS:
-7.2117
Net Cash Flow:
$-5.11M
1W Performance:
-9.76%
1M Performance:
-44.78%
6M Performance:
+621.95%
1Y Performance:
+880.57%
1-Day Range:
$2.12
$3.3199
1-Week Range:
$2.12
$3.3199
52-Week Range:
$0.197
$8.90
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
2.22 | 3.96M | 1.31M | -7.47M | -5.11M | -7.2117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Scisparc Ltd Stock (SPRC) Latest News
SciSparc Ltd. to Acquire Xylo’s Patents for Endoscopic Systems - TipRanks
SciSparc’s Patent Surge: Buy or Hold? - StocksToTrade
SciSparc Ltd. (SPRC) Stock: Jumps as Company Expands into High-Growth GERD Device Market - parameter.io
Why SciSparc Stock Is Gaining Today - Benzinga
SciSparc Shares Surge After Company Moves to Acquire GERD Treatment Technology - MSN
SciSparc Stocks Surge: A Strategic Leap Forward? - timothysykes.com
SciSparc to acquire MUSE endoscopic system patents from Xylo By Investing.com - Investing.com Nigeria
SciSparc stock soars after acquiring GERD treatment technology - Investing.com
SciSparc to acquire treasury of patents for medical endoscopy systems - TipRanks
SciSparc to acquire endoscopic system patents from Xylo Technologies By Investing.com - Investing.com South Africa
Scisparc to acquire treasury of patents for innovative medical endoscopy systems - MarketScreener
Scisparc shares climb 27.5% premarket; co says will buy a treasury of patents, trademarks and intellectual property rights from Xylo - MarketScreener
SciSparc Ltd. Signs Agreement to Acquire Patent and Intellectual Property Portfolio for Innovative MUSE™ Endoscopic System from Xylo Technologies Ltd. - Quiver Quantitative
SciSparc (Nasdaq: SPRC) to acquire MUSE GERD device IP for 19.99% equity - Stock Titan
SciSparc Stock Soars Pre-Market After Snapping Up Patents For Next-Gen Endoscopy Tech - Stocktwits
SciSparc, Clearmind Medicine file Israeli patent application for depression - MSN
SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will SciSparc Ltd. stock recover faster than peersGlobal Markets & Risk Managed Investment Signals - newser.com
How SciSparc Ltd. stock compares to industry benchmarksJuly 2025 Weekly Recap & Technical Buy Zone Confirmations - newser.com
SciSparc Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
SciSparc Announces New Patent Filing for Depression Treatment - TipRanks
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
[6-K] SciSparc Ltd. Current Report (Foreign Issuer) | SPRC SEC FilingForm 6-K - Stock Titan
SciSparc subsidiary files patent for depression treatment combination By Investing.com - Investing.com Australia
SciSparc subsidiary files patent for depression treatment combination - Investing.com
SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression - The Manila Times
SciSparc Ltd. Partner NeuroThera Labs Advances Depression Treatment with New Patent Application for Combination Therapy - Quiver Quantitative
SciSparc: Neurothera Labs Announces Israeli Patent - GlobeNewswire
Will SciSparc Ltd. stock gain from lower inflationWeekly Profit Summary & Weekly High Potential Stock Alerts - newser.com
Is SciSparc Ltd. stock entering bullish territoryJuly 2025 Selloffs & Verified Trade Idea Suggestions - newser.com
Is SciSparc Ltd. stock in correction or buying zone2025 Support & Resistance & Verified Swing Trading Watchlists - newser.com
Is SciSparc Ltd. stock a top momentum playMarket Risk Summary & Capital Efficient Trading Techniques - newser.com
SciSparc Ltd. Releases Interim Financial Results for H1 2025 - MSN
How SciSparc Ltd. stock performs in interest rate cyclesJuly 2025 Earnings & Verified Momentum Watchlists - newser.com
What analysts say about SciSparc Ltd stockLong-Term Growth Stocks & Discover Stocks Experts Are Watching - earlytimes.in
Will SciSparc Ltd. bounce back from current supportJuly 2025 Setups & Fast Entry High Yield Tips - newser.com
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 - MarketScreener
Scisparc Ltd. Net Worth (2025) - GuruFocus
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.76%
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):